Business
UroGen Pharma Promotes Key Personnel Focused on Commercial Operations and Expanded Clinical Development
Experienced Leadership Team with Established Track Record Prepares for Transition to a Commercial Stage Organization NEW YORK--(BUSINESS WIRE)-- UroGen
About this update from Urogen Pharma Ltd.
[{"type":"text","content":"\nExperienced Leadership Team with Established Track Record Prepares for Transition to a Commercial Stage Organization\n\n NEW YORK--(BUSINESS WIRE)--\nUroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced promotions for key members of the Executive Leadership Team. These appointments will better position the Company for its next growth phase with the anticipated approval and launch of its first product candidate, UGN-101 (mitomycin gel) for instillation, for the treatment of patients with low-grade upper tract urothelial cancer (LG UTUC). In December 2019, the U.S. Food and Drug Administration accepted for filing and granted priority review for the Company’s UGN-101 application and assigned a Prescription Drug User Fee Act (PDUFA) action date of April 18, 2020.\n\n\nEffective April 1, 2020, the following individuals will be promoted to the following roles:\n\n\n\nJeff Bova, Chief Commercial Officer\n\n\nMarina Konorty, PhD, Executive Vice President, Research & Development and Technical Operations\n\n\nJames Ottinger, RPh, Executive Vice President, Regulatory Affairs and Quality\n\n\nElyse Seltzer, MD, Chief Development Officer\n\n\n\n“I am delighted to announce the promotions of these outstanding colleagues and to see firsthand how they will continue to help transform the Company with their expanded responsibilities. UroGen’s accomplishments to date have been a direct result of their tireless efforts, and I look forward to continuing to work with this talented and experienced team as we together embark on the most transformational time for our company,” said Liz Barrett, President and Chief Executive Officer of UroGen. “We are rapidly approaching potential approval and commercialization of our lead product candidate, UGN-101, for the treatment of patients with low-grade upper tract urothelial cancer. With this team, I’m confident in our ability to deliver on the promise of our RTGel™ platform and advance our pipeline of product candidates for patients in areas of unmet need.”\n\n\nJeff Bova, Chief Commercial Officer\n\n\nMr. Bova joined UroGen in 2017 and most recently served as UroGen’s Senior Vice President of Commercial. He is an experienced pharmaceutical industry executive...